IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening viral diseases in the areas of cervical cancer, HIV/AIDS, hepatitis, and organ transplant rejection. The company is privately held and located in Menlo Park, California.
IncellDx, Inc. is committed to bringing personalized medicine to infectious disease testing through innovative molecular diagnostic products.
IncellDx technology combines Simultaneous Ultrasensitive Signal-amplified Hybridization In Situ (SUSHI) with a novel, cell-based instrument capable of quantifying molecular biomarkers inside intact cells. This allows protein and gene expression to be measured by distinct cell type which aids both diagnosis and disease localization. The technology is ultra-fast, inexpensive, highly reproducible, and able to perform complex molecular testing without DNA extraction or amplification.